Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-10-27 Regulatory Filings
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-10-27 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration, specifically for Entrada Therapeutics, Inc. The document length is short (3599 characters) and it contains no financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-10-26 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1, specifically requesting acceleration of the effectiveness of the Registration Statement. It mentions distribution of the Preliminary Prospectus and compliance with Rule 15c2-8. The document is short (1883 characters) and is a correspondence related to a regulatory filing process, not the actual registration statement or prospectus itself. It does not contain financial statements or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and correspondence with the SEC that do not fit other categories.
2021-10-26 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a formal communication related to the registration process for securities, specifically under the Securities Act of 1933. The content is procedural and does not contain financial data, audit information, or report content. It is not a report itself but an announcement/request related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-10-26 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC by Entrada Therapeutics, Inc. The Form S-1 is a registration statement used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the offering, company overview, risk factors, management discussion, financial data, and other disclosures typical of a registration statement. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual filing text. Confidence is high due to the clear identification of the form and its purpose.
2021-10-25 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on a Draft Registration Statement on Form S-1. It discusses amendments and responses to SEC staff comments regarding the registration statement. The document is not the registration statement itself but a correspondence related to it. It is a regulatory filing related to the registration process, not a financial report, earnings release, or other specific report type. The document length is short (3222 characters) and is a letter format, indicating it is a Regulatory Filing (RNS) rather than the actual Form S-1 or an announcement of a report publication (RPA).
2021-10-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.